These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 954347)

  • 21. Influence of food on the comparative bioavailability of a fast- and slow-release dosage form of quinidine gluconate.
    Spénard J; Sirois G; Gagnon MA
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):1-9. PubMed ID: 6832862
    [No Abstract]   [Full Text] [Related]  

  • 22. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.
    Covinsky JO; Russo J; Kelly KL; Cashman J; Amick EN; Mason WD
    J Clin Pharmacol; 1979; 19(5-6):261-9. PubMed ID: 469022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and absolute bioavailability of diltiazem in humans.
    Ochs HR; Knüchel M
    Klin Wochenschr; 1984 Apr; 62(7):303-6. PubMed ID: 6727272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.
    Fleuren HL; Thien TA; Verwey-van Wissen CP; van Rossum JM
    Eur J Clin Pharmacol; 1979 Feb; 15(1):35-50. PubMed ID: 421727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of caffeine on the oral absorption and disposition of quinidine.
    Zeller FP; Ueda CT; Wulf BG; Meyers DG
    Clin Pharm; 1984; 3(1):72-5. PubMed ID: 6697677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digoxin bioavailability: formulations and rates of infusions.
    Marcus FI; Dickerson J; Pippin S; Stafford M; Bressler R
    Clin Pharmacol Ther; 1976 Sep; 20(3):253-9. PubMed ID: 954346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Digoxin bioavailability during quinidine administration.
    Hager WD; Mayersohn M; Graves PE
    Clin Pharmacol Ther; 1981 Nov; 30(5):594-9. PubMed ID: 7297019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
    Nave R; Bethke TD; van Marle SP; Zech K
    Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relative bioavailability of various quinidine preparations in man after a single oral dose].
    Terhaag B; Gieszinger U
    Pharmazie; 1982 Dec; 37(12):848-50. PubMed ID: 7163373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.
    Meyer MC; Straughn AB; Lieberman P; Jacob J
    J Clin Pharmacol; 1982; 22(2-3):131-4. PubMed ID: 7068936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative bioavailability of three commercial quinidine dosage forms.
    Sirois G; Eshaque M; Chabot M
    Biopharm Drug Dispos; 1980; 1(4):167-77. PubMed ID: 7448345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of quinidine gluconate injection in a polyvinyl chloride infusion system.
    Darbar D; Dell'Orto S; Wilkinson GR; Roden DM
    Am J Health Syst Pharm; 1996 Mar; 53(6):655-8. PubMed ID: 8800971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal absorption of quinidine from some solutions and commercial tablets.
    Guentert TW; Upton RA; Holford NH; Bostrom A; Riegelman S
    J Pharmacokinet Biopharm; 1980 Jun; 8(3):243-55. PubMed ID: 7420269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid elimination of quinidine in pediatric patients.
    Szefler SJ; Pieroni DR; Gingell RL; Shen DD
    Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
    Kessler KM; Humphries WC; Black M; Spann JF
    Am Heart J; 1978 Nov; 96(5):627-35. PubMed ID: 263396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet.
    Martinez MN; Pelsor FR; Shah VP; Skelly JP; Honigberg IL; Hemingway SM; Gallo JM; Kotzan JA; Zaman R; Brown WJ
    Biopharm Drug Dispos; 1990; 11(1):17-29. PubMed ID: 2322634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets.
    Dahl JR; Ueda CT; Meyers DG; Wulf BG
    DICP; 1990; 24(7-8):685-8. PubMed ID: 2375136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.